Abbott Receives Positive Opinion for HUMIRA in Ulcerative Colitis from EMA's CHMP

Loading...
Loading...
Abbott
ABT
today announced that the European Committee for Medicinal Products for Human Use (
CHMP
) has issued a positive opinion for HUMIRA (adalimumab) in adults with moderate to severely active ulcerative colitis (UC) who have not responded to, cannot tolerate or have medical contraindications to conventional therapies. Based on the CHMP's positive opinion, a final decision from the European Commission is anticipated in the next few weeks. Upon final decision, HUMIRA will be the first and only self-injectable biologic therapy available for moderate to severe UC patients.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...